Tarsus Pharmaceuticals Stock Volatility Indicators Normalized Average True Range
| TARS Stock | USD 74.49 1.23 1.68% |
| Symbol |
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Normalized Average True Range is used to analyze tradable apportunities for Tarsus Pharmaceuticals across different markets.
Tarsus Pharmaceuticals Technical Analysis Modules
Most technical analysis of Tarsus Pharmaceuticals help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Tarsus from various momentum indicators to cycle indicators. When you analyze Tarsus charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Tarsus Pharmaceuticals Net Worth Estimate
Tarsus Pharmaceuticals is a large-cap equity in Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care categories. Market multiples reflect competitive positioning. We review the company from a portfolio-construction standpoint emphasizing diversification and stability.
Methodology
Unless otherwise specified, financial data for Tarsus Pharmaceuticals is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Tarsus (USA Stocks:TARS) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions Valuation estimates and intrinsic-value models use inputs from public financial disclosures and may not represent market consensus.
Assumptions
Information presented is compiled from public filings and market reference sources and official institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR. Updates can be delayed depending on reporting conventions. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.Analyst Sources
Tarsus Pharmaceuticals is covered by 8 analysts. 4 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Evercore ISI, Morgan Stanley, BMO Capital Markets, Oppenheimer & Co., Guggenheim Securities, HSBC Global Research, Raymond James, Bernstein Research, among others. Updates may occur throughout the day.
Learn to be your own money manager
Tracking Tarsus Pharmaceuticals inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Did you try this?
Run Aroon Oscillator Now
Aroon OscillatorAnalyze current equity momentum using Aroon Oscillator and other momentum ratios |
| All Next | Launch Module |
Tarsus Pharmaceuticals pair trading
Pair trading with Tarsus Pharmaceuticals can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Tarsus Pharmaceuticals Pair Trading
Tarsus Pharmaceuticals Pair Trading Analysis
Identifying correlated replacements for Tarsus Pharmaceuticals is particularly important in concentrated portfolios where Tarsus Pharmaceuticals represents a large allocation. A poor substitute could introduce unintended factor or sector risks that persist beyond the required waiting period.
Correlation is not causation, but for Tarsus Pharmaceuticals it is a practical tool. High correlations between Tarsus Pharmaceuticals and a potential addition to the portfolio flag concentrated exposure, while low correlations signal diversification potential.
Correlation analysis and pair evaluation for Tarsus Pharmaceuticals can support hedging context. The method can be applied across sectors and broader equity sets.Additional Tools for Tarsus Stock Analysis
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |